Clinical Trials · NCT02098395
The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 835
- Start date
- May 2014
- Locations
- 120 sites, 13 countries
- Primary endpoint
- Change From Baseline in Glycosylated Haemoglobin (HbA1c)